Reid Merryman, Md
Clinical trials sponsored by Reid Merryman, Md, explained in plain language.
-
Three-Pronged attack on stubborn blood cancers
Disease control Recruiting nowThis study is testing a combination of three drugs—epcoritamab, zanubrutinib, and rituximab—to see how well they work and how safe they are for people with follicular lymphoma or marginal zone lymphoma that has come back or hasn't responded to previous treatments. About 45 partic…
Phase: PHASE2 • Sponsor: Reid Merryman, MD • Aim: Disease control
Last updated Apr 04, 2026 00:20 UTC
-
New drug duo aims to train immune system to fight blood cancer
Disease control Recruiting nowThis study is testing a new combination of two immune-based drugs, epcoritamab and rituximab, for people with follicular lymphoma who have not yet received any treatment. The goal is to see how well and how safely this drug pair works to control the cancer. About 100 participants…
Phase: PHASE2 • Sponsor: Reid Merryman, MD • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC